Impact of CYP2C19 genotype on escitalopram exposure and establishment of a dose algorithm for genotype-based individualization of escitalopram therapy

被引：0
|
作者：
Jukic, M. [1 ]
Molden, E. [2 ]
Ingelman-Sundberg, M. [1 ]
机构：
[1] Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden
[2] Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Oslo, Norway
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2017年 / 27卷
关键词：
D O I：
10.1016/S0924-977X(17)31537-7
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.2.f.017
引用
收藏
页码：S856 / S856
页数：1
相关论文
共 50 条
  • [21] Dose optimization of omeprazole according to the CYP2C19 genotype.
    Park, So-Young
    Bae, Jung-Woo
    Choi, Chang-Ik
    PHARMACOTHERAPY, 2012, 32 (10): : E236 - E236
  • [22] CYP2C19 Genotype and Cardiovascular Events
    Mega, Jessica L.
    Topol, Eric J.
    Sabatine, Marc S.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (14): : 1482 - 1483
  • [23] CYP2C19 genotype: a moving target?
    Zembles, Tracy N.
    Marcuccilli, Charles J.
    Sander, Tara L.
    Simpson, Pippa
    PHARMACOTHERAPY, 2012, 32 (10): : E236 - E236
  • [24] Development of a CYP2C19 Genotype Guided Dosing Algorithm for Voriconazole
    Mangal, Naveen
    Hamadeh, Issam
    Samant, Tanay
    Schmidt, Stephan
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S53 - S53
  • [25] CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants:: a first step towards subpopulation-specific dosages
    Kirchheiner, J
    Brosen, K
    Dahl, ML
    Gram, LF
    Kasper, S
    Roots, I
    Sjöqvist, F
    Spina, E
    Brockmöller, J
    ACTA PSYCHIATRICA SCANDINAVICA, 2001, 104 (03) : 173 - 192
  • [26] Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients
    Rudberg, I.
    Mohebi, B.
    Hermann, M.
    Refsum, H.
    Molden, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (02) : 322 - 327
  • [27] IMPACT OF CYP2C19 PHENOTYPES ON ESCITALOPRAM PHARMACOKINETICS AND EVALUATION OF PUPILLOMETRY AS A BIOMARKER OF SEROTONERGIC EFFECT
    Noehr-Jensen, L.
    Zwisler, S. T.
    Larsen, F.
    Sindrup, S. H.
    Damkier, P.
    Brosen, K.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 31 - 32
  • [28] CYP2D6 and CYP2C19 genotype based dose recommendations in antidepressants.
    Stingl, J
    Roots, I
    Brockmöller, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 130 - 130
  • [29] Pharmacogenetics of CYP2C19 and Response to Escitalopram in Autism Spectrum Disorders (ASD)
    Bishop, Jeffrey R.
    Najjar, Fedra
    Owley, Thomas
    Stephen, Guter
    Cook, Edwin H.
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S516 - S517
  • [30] Rapid CYP2C19 Genotype Testing: Comparison between Spartan RX CYP2C19 and Verigene CYP2C19
    Zhou, Y.
    Armstead, A. R.
    Coshatt, G. M.
    Brott, B. C.
    Sankaranarayanan, A.
    Limdi, N. A.
    Harada, S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 845 - 845
12345